Cargando…

Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade

BACKGROUND: The search for biomarkers to identify ideal candidates for immune checkpoint inhibitor (ICI) therapy is fundamental. In this study, we analyze peripheral blood CD3+HLADR+ cells (activated T-cells) as a novel biomarker for ICI therapy and how its association to certain gut microbiome spec...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorgulho, Joao, Roderburg, Christoph, Beier, Fabian, Bokemeyer, Carsten, Brümmendorf, Tim H., Luedde, Tom, Loosen, Sven H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495594/
https://www.ncbi.nlm.nih.gov/pubmed/37705980
http://dx.doi.org/10.3389/fimmu.2023.1206953
_version_ 1785104931551707136
author Gorgulho, Joao
Roderburg, Christoph
Beier, Fabian
Bokemeyer, Carsten
Brümmendorf, Tim H.
Luedde, Tom
Loosen, Sven H.
author_facet Gorgulho, Joao
Roderburg, Christoph
Beier, Fabian
Bokemeyer, Carsten
Brümmendorf, Tim H.
Luedde, Tom
Loosen, Sven H.
author_sort Gorgulho, Joao
collection PubMed
description BACKGROUND: The search for biomarkers to identify ideal candidates for immune checkpoint inhibitor (ICI) therapy is fundamental. In this study, we analyze peripheral blood CD3+HLADR+ cells (activated T-cells) as a novel biomarker for ICI therapy and how its association to certain gut microbiome species can indicate individual treatment outcomes. METHODS: Flow cytometry analysis of peripheral mononuclear blood cells (PBMCs) was performed on n=70 patients undergoing ICI therapy for solid malignancies to quantify HLA-DR on circulating CD3+ cells. 16s-rRNA sequencing of stool samples was performed on n=37 patients to assess relative abundance of gut microbiota. RESULTS: Patients with a higher frequency of CD3+HLADR+ cells before treatment initiation showed a significantly reduced tumor response and overall survival (OS), a worst response and experienced less toxicities to ICI therapy. As such, patients with a frequency of CD3+HLADR+ cells above an ideal cut-off value of 18.55% had a median OS of only 132 days compared to 569 days for patients below. Patients with increasing CD3+HLADR+ cell counts during therapy had a significantly improved OS. An immune signature score comprising CD3+HLADR+ cells and the neutrophil-lymphocyte ratio (NLR) was highly significant for predicting OS before and during therapy. When allied to the relative abundance of microbiota from the Burkholderiales order and the species Bacteroides vulgatus, two immune-microbial scores revealed a promising predictive and prognostic power. CONCLUSION: We identify the frequencies and dynamics of CD3+HLADR+ cells as an easily accessible prognostic marker to predict outcome to ICIs, and how these could be associated with immune modulating microbiome species. Two unprecedented immune-microbial scores comprising CD3+HLADR+, NLR and relative abundance of gut bacteria from the Burkhorderiales order or Bacteroides vulgatus species could accurately predict OS to immune checkpoint blockade.
format Online
Article
Text
id pubmed-10495594
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104955942023-09-13 Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade Gorgulho, Joao Roderburg, Christoph Beier, Fabian Bokemeyer, Carsten Brümmendorf, Tim H. Luedde, Tom Loosen, Sven H. Front Immunol Immunology BACKGROUND: The search for biomarkers to identify ideal candidates for immune checkpoint inhibitor (ICI) therapy is fundamental. In this study, we analyze peripheral blood CD3+HLADR+ cells (activated T-cells) as a novel biomarker for ICI therapy and how its association to certain gut microbiome species can indicate individual treatment outcomes. METHODS: Flow cytometry analysis of peripheral mononuclear blood cells (PBMCs) was performed on n=70 patients undergoing ICI therapy for solid malignancies to quantify HLA-DR on circulating CD3+ cells. 16s-rRNA sequencing of stool samples was performed on n=37 patients to assess relative abundance of gut microbiota. RESULTS: Patients with a higher frequency of CD3+HLADR+ cells before treatment initiation showed a significantly reduced tumor response and overall survival (OS), a worst response and experienced less toxicities to ICI therapy. As such, patients with a frequency of CD3+HLADR+ cells above an ideal cut-off value of 18.55% had a median OS of only 132 days compared to 569 days for patients below. Patients with increasing CD3+HLADR+ cell counts during therapy had a significantly improved OS. An immune signature score comprising CD3+HLADR+ cells and the neutrophil-lymphocyte ratio (NLR) was highly significant for predicting OS before and during therapy. When allied to the relative abundance of microbiota from the Burkholderiales order and the species Bacteroides vulgatus, two immune-microbial scores revealed a promising predictive and prognostic power. CONCLUSION: We identify the frequencies and dynamics of CD3+HLADR+ cells as an easily accessible prognostic marker to predict outcome to ICIs, and how these could be associated with immune modulating microbiome species. Two unprecedented immune-microbial scores comprising CD3+HLADR+, NLR and relative abundance of gut bacteria from the Burkhorderiales order or Bacteroides vulgatus species could accurately predict OS to immune checkpoint blockade. Frontiers Media S.A. 2023-08-29 /pmc/articles/PMC10495594/ /pubmed/37705980 http://dx.doi.org/10.3389/fimmu.2023.1206953 Text en Copyright © 2023 Gorgulho, Roderburg, Beier, Bokemeyer, Brümmendorf, Luedde and Loosen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Gorgulho, Joao
Roderburg, Christoph
Beier, Fabian
Bokemeyer, Carsten
Brümmendorf, Tim H.
Luedde, Tom
Loosen, Sven H.
Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
title Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
title_full Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
title_fullStr Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
title_full_unstemmed Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
title_short Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
title_sort peripheral blood cd3+hladr+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495594/
https://www.ncbi.nlm.nih.gov/pubmed/37705980
http://dx.doi.org/10.3389/fimmu.2023.1206953
work_keys_str_mv AT gorgulhojoao peripheralbloodcd3hladrcellsandassociatedgutmicrobiomespeciespredictresponseandoverallsurvivaltoimmunecheckpointblockade
AT roderburgchristoph peripheralbloodcd3hladrcellsandassociatedgutmicrobiomespeciespredictresponseandoverallsurvivaltoimmunecheckpointblockade
AT beierfabian peripheralbloodcd3hladrcellsandassociatedgutmicrobiomespeciespredictresponseandoverallsurvivaltoimmunecheckpointblockade
AT bokemeyercarsten peripheralbloodcd3hladrcellsandassociatedgutmicrobiomespeciespredictresponseandoverallsurvivaltoimmunecheckpointblockade
AT brummendorftimh peripheralbloodcd3hladrcellsandassociatedgutmicrobiomespeciespredictresponseandoverallsurvivaltoimmunecheckpointblockade
AT lueddetom peripheralbloodcd3hladrcellsandassociatedgutmicrobiomespeciespredictresponseandoverallsurvivaltoimmunecheckpointblockade
AT loosensvenh peripheralbloodcd3hladrcellsandassociatedgutmicrobiomespeciespredictresponseandoverallsurvivaltoimmunecheckpointblockade